尖峰集团(600668.SH)：子公司撤回药品注册临床试验申请

Core Viewpoint - Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn its drug registration clinical trial application for "C2235 and C2235 tablets" due to the need for further documentation improvement [1] Group 1: Company Actions - Jianfeng Pharmaceutical received a termination notice from the National Medical Products Administration regarding the drug registration application [1] - The decision to withdraw the application was made after careful consideration, indicating a proactive approach to ensure compliance and quality [1] Group 2: Future Plans - The company plans to resubmit the drug registration clinical trial application after completing the necessary research improvements [1]